Telix Pharmaceuticals (ASX:TLX) said that its Phase 2 IPAX-Linz study of drug candidate TLX101, in combination with external beam radiation therapy (EBRT), was well tolerated and showed no serious adverse events in patients with brain cancer, according to a Wednesday filing with the Australian bourse.
The study indicated a median overall survival of 12.4 months from treatment initiation, and 32.2 months from diagnosis, the company said.
The company has submitted an ethics approval request for a registration-enabling study of TLX101 in recurrent brain cancer, the filing added.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。